Otros idiomas Karyopharm Therapeutics Inc.

Acciones

KPTI

US48576U1060

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
1,06 ^USD	0,00 %		-9,40 %	+22,54 %

24/04	Karyopharm Therapeutics Inc. Anuncia Presentaciones en Cáncer de Endometrio y Mielofibrosis en la Reunión Anual 2024 de la Sociedad Americana de Oncología Clínica	CI
13/03	Transcript : Karyopharm Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting	25/04
Karyopharm Therapeutics Inc. Announces Presentations in Endometrial Cancer and Myelofibrosis At the 2024 American Society of Clinical Oncology Annual Meeting	24/04
Karyopharm Therapeutics : April 19, 2024	19/04
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/04
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences	06/03
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	04/03
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/03
Karyopharm Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress	01/03
Karyopharm Therapeutics: Q4 Earnings Snapshot	29/02
Karyopharm Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Posts Q4 Revenue $33.7M, vs. Street Est of $33.6M	29/02
Karyopharm Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2024	29/02
North American Morning Briefing : Fed's Preferred -2-	29/02
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024	22/02
North American Morning Briefing : Stock Futures -2-	21/02
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/02
Karyopharm Therapeutics Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year 2023	08/01
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives	08/01
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	03/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Karyopharm Therapeutics Inc.

Acciones

KPTI

US48576U1060

Otros idiomas

Filtros